Wells Fargo
JAZZ icon

Wells Fargo’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wells Fargo’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-22,500
Closed -$264K – 6553
2019
Q3 		$264K Hold
22,500
– – ﹤0.01% 4791
2019
Q2 		$168K Buy
+22,500
New +$3.02M ﹤0.01% 5067

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wells Fargo's JAZZ Position: Q1 2026 in Review

Wells Fargo reduced its Jazz Pharmaceuticals (JAZZ) stake by 32% in Q1 2026, selling an estimated $5.6M and leaving 68,488 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1830.

Wells Fargo first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $308M in Q2 2014. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Wells Fargo held 68,488 shares of Jazz Pharmaceuticals worth $12.9M as of Q1 2026.
  • Wells Fargo sold 32,055 Jazz Pharmaceuticals shares in Q1 2026, an estimated $5.6M.
  • Jazz Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1830 holding.
  • Wells Fargo first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Jazz Pharmaceuticals position peaked at $308M in Q2 2014.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.